Insitro announces collaboration with AstraZeneca to discover treatments for MASH and cardiomyopathies
AZN•Insitro announced a strategic collaboration with AstraZeneca for AI-enabled discovery of novel therapeutics for MASH and cardiomyopathies. Insitro will receive $40 million upfront and is eligible for up to about $1.46 billion in potential discovery, development and commercial milestones.
1. Collaboration terms
Insitro announced a strategic collaboration with AstraZeneca to use AI-enabled discovery to identify novel therapeutics for MASH and cardiomyopathies. Under the terms, Insitro will receive $40 million upfront and is eligible for up to about $1.46 billion in potential discovery, development and commercial milestones.
